Shire confirms strong product growth in first half
8th Aug 2016 07:15
(ShareCast News) - First-half results from Shire confirmed the drugmaker's strong performance so far in 2016, completing two acquisitions and continuing to grow its underlying business. Just a week after it unveiled a sparkling set of second-quarter results, Shire posted interim numbers that showed
Read moreThursday broker round-up
4th Aug 2016 11:59
(ShareCast News) - Next: Goldman Sachs reiterates sell with a target price of 4800p. Standard Chartered: JP Morgan maintains overweight with a 800p target. Shire: JP Morgan reiterates overweight with a 6300p target. Genus: HSBC stays at buy with a 2200p target. Nichols: UBS keeps at buy with a ta
Read moreWednesday round-up
3rd Aug 2016 12:13
(ShareCast News) - Laird: UBS upgrades to buy with a target price of 350p. Direct Line Group: Deutsche Bank maintains buy with a 435p target. Associated British Foods: Exane BNP Paribas reiterates outperform with a 3300p target. Sky: Goldman Sachs reiterates buy with a target price of 1029p. Fres
Read moreShire hikes guidance after Baxalta adds to forecast-beating second quarter
2nd Aug 2016 12:04
(ShareCast News) - Shire has upgraded its full year guidance and upped its interim dividend after it enjoyed a strong performance in the first half of the year and completed the acquisition of Baxalta. With the Baxalta acquisition incorporated since 3 June and existing drugs generating double dig
Read moreTuesday preview: FTSE earnings in focus
1st Aug 2016 12:24
(ShareCast News) - With earnings season in full swing, corporate results on the FTSE 100 and 250 will dominate Tuesday's agenda. Meggitt reports its first half results with analysts expecting the aerospace engineer to reveal higher revenues. UBS forecasts a 10.8% increase in group revenue to £846m,
Read moreShire gains US approval for Baxalta's improved Baxject haemophilia system
1st Aug 2016 12:18
(ShareCast News) - Shire has received US regulatory approval for an improved haemophilia-A treatment developed by recently acquired Baxalta. The US Food and Drug Administration (FDA) approved the Baxject III reconstitution system for Adynovate, a new preparation for the recombinant antihemophilic wh
Read moreShire swaps three drug programmes for equity in Chronos Therapeutics
21st Jul 2016 11:02
(ShareCast News) - Shire has offloaded three pre-clinical development programmes to private drug developer Chronos Therapeutics in return for an equity stake in the Oxford-based company and future royalty rights. Chronos, which is well funded thanks to a 2013 funding round from investors including O
Read moreShire's eye drug approved by US FDA
12th Jul 2016 07:10
(ShareCast News) - The US Food and Drug Administration has approved Shire's lifitegrast eye drops for treating signs and symptoms of dry eye disease. Lifitegrast, to be sold under the Xiidra name, is expected to launch in the third quarter. "An estimated 16m adults in the U.S. are diagnosed with dr
Read moreSector movers: House builders and banks rally
8th Jul 2016 18:37
(ShareCast News) - House builders, banks topped the blue-chip winners' ladder at close of play on Friday, having last week and this suffered under the shadow of Britain's non-binding vote to quit the EU. Taylor Wimpey, Berkeley Group, Barratt Developments and Persimmon sprinted higher with gains of
Read moreShire drug tests shows first ever effects on reducing prenatal complications
30th Jun 2016 13:33
(ShareCast News) - While a drug being tested by Shire failed to a treat a form of infant blindness as hoped, it instead demonstrated positive effects on severe complications related to lung and brain damage. The drug, currently called SHP607 helped reduce the occurrence of severe bronchopulmonary dy
Read moreShire eyes adult ADHD drug application in 2016 after encouraging results
29th Jun 2016 12:46
(ShareCast News) - Shire plans to resubmit a new drug application in the US for its potential treatment for adult attention-deficit/hyperactivity disorder (ADHD) after efficacy and safety trials produced positive results. A four-week trial in 275 adults for SHP465, the name for its triple-bead mixed
Read moreCredit Suisse sees 30% chance of 'Brexit lite', recommends buying UK dollar earners
29th Jun 2016 09:11
(ShareCast News) - In its latest global equity strategy note, Credit Suisse said there was a 30% chance of a 'Brexit lite' and no change in governing party until 2020. "We have a 30% chance of a second referendum which would take place if Boris Johnson is able to negotiate better terms (i.e. a brake
Read moreCredit Suisse sees rising odds of Brexit 'lite', lowers year-end Footsie target
27th Jun 2016 11:36
(ShareCast News) - Credit Suisse marked down its year-end target for the Footsie but was not overly pessimistic, emphasising that it saw rising odds of a 'Brexit lite', versus a hard Brexit which would include invoking Article 50 of the Lisbon Treaty, although in the opinion of its analysts there wa
Read moreLeave vote would have limited impact on FTSE, says SpreadCo analyst
21st Jun 2016 13:12
(ShareCast News) - Although consensus is that the FTSE 100 will rally if voters in the UK opt to remain in the European Union on Thursday and sell off on a Leave vote, the overall impact of an exit on London stocks may be limited, said SpreadCo analyst David Morrison. "The damage to the FTSE100 as a
Read moreWednesday broker round-up
15th Jun 2016 15:32
(ShareCast News) - Arrow Global Group: Goldman Sachs reiterates buy with a target price of 340p. Crest Nicholson: JP Morgan keeps at overweight with a 700p target. Shire: Exane BNP Paribas stays at outperform with a target price of 5700p and Jefferies keeps at buy with a target price of 5500p. Woo
Read more